February 11, 2015
Sanofi seeks growth by diversifying its activities and its worldwide presence. We have seven growth platforms; emerging markets, diabetes, vaccines, consumer healthcare, animal health, genzyme and innovative products.
Emerging markets - we are the leading healthcare company as a result of a long and strong heritage
Diabetes treatment - our vision is to respond to all patients' healthcare needs, not just treatments, but innovative services and technology
Human vaccines - we have developed a strong pipeline and have the ability to respond to public health needs
Consumer healthcare - we are the fifth largest player globally
Animal health - one of the world's leading companies dedicated to the research, development, manufacture and delivery of innovative pharmaceuticals and vaccines for animals
Genzyme - investment to ensure product availability and enhance production infrastructure
Innovative products - developing innovative medicines is our core strength and we will continue to respond to future public health needs
The world's healthcare needs cannot be met by a single type of therapy. New products such as biotech-derived medicines, generics and vaccines will be our focus in finding and developing these new opportunities.
Alongside our portfolio of prescription medicines, we are strengthening our activities in other areas including vaccines, OTC consumer healthcare products, branded generics and services. Worldwide, these are all adapted to each region, country and patient.
Our growth strategy is based on acquisitions and partnerships that create shareholder value by creating or reinforcing platforms for long-term growth.
Sanofi is committed to unleashing creativity and innovation by actively engaging with third parties. The acquisitions of Genzyme, Zentiva, Medley, Kendricks, Acambis and Symbion Consumer, as well as Merial in animal health, are the first steps in this direction.
Sanofi in the UK
Find out more about Sanofi UK's business units and locations, our investment in research and development, and our product pipeline